Our studies suggest that, regardless of the exact role of GLS2 in cancers, cancer researchers interested in studying glutamine addiction in mitotic diseases (including cancers [116]) must take into account the presence of the GTωA pathway in these cells. The gene discussed is GLS2; the disease is cancer.